HealthcareLarge capRs 55,739 crRs 19.8 cr traded a dayMultinationalsHealthcarePharmaceuticals
Close on 2026-08-21
26,230.00
+0.42%
52-week range14% of the way up
25,180.0032,575.00
Market cap
55,739 cr
P/E (TTM)
34.5×
industry 44×
EPS (TTM)
759.85
Revenue YoY
+4.3%
Q1 FY27
Profit YoY
+17.1%
Net margin
23.6%
+2.6pt vs a year ago
Growth trend
-2.2pt
vs last quarter’s YoY
1 month
-8.6%
Below 52w high
24.2%
RSI (14)
24
oversold
Daily swing
1.9%
average true range
Volume
1.0×
vs 20-day average
Traded
Rs 20 cr
median day
Close200-day averageMaterial filing
260 sessions · hover for the filing behind a move
1 week
−3.07%
1 month
−8.57%
3 months
−5.00%
6 months
−0.47%
1 year
−19.28%
The read
written from the numbers on this page
The evidence leans negative2 supporting, 4 against, 2 worth knowing
Supporting
matches near a 52-week low, which has beaten the market by +0.45 points over 20 sessions across 47,393 past signals
priced at 35× earnings against an industry median of 44× — 22% below its peers
Against
trading 3% below its 200-day average
at 14% of its 52-week range — nearly everyone who bought in the past year is underwater
down 19% over twelve months
1 of the scans it matches has historically underperformed the market
Worth knowing
RSI at 24 is washed out — historically the better half of this site's measured edge comes from exactly this condition
revenue grew 4% year on year in the quarter ending 2026-06-30
ABBOTINDIA sits in Multinationals, Healthcare, Pharmaceuticals — worth checking whether the whole group is moving together or whether this name is doing it alone.
What would change this read: a close back above 27,177, its 200-day average.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
What is working, what is not
read from the filings, with the figure behind every line
Working3
Net margin moved from 21.0% to 23.6%.
21.0%23.6%
Net profit +17.1% year on year, Rs 366 cr to Rs 429 cr.
+17.1%Rs 366 crRs 429 cr
Profit grew faster than revenue, +17.1% against +4.3%.
+17.1%+4.3%
Needs watching
Nothing in the filings stands out either way.
Every figure here is computed from the company’s own filings. The wording is generated directly from the figures.
How it has performed
price return over each window, measured against zero
What the scans say today
3 of 47 matched on 2026-08-21
ABBOTINDIA matches 3 of the 47 scans today, across 2 different kinds of evidence.
ABBOTINDIA trades at 35× trailing earnings, close to its median of 37× over this window. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
AGM / EGM filings were typically +0.00pt vs the market over the next 5 sessions (n=4,362) · Other filing filings were typically -0.08pt vs the market over the next 5 sessions (n=12,093) · Results filings were typically -0.52pt vs the market over the next 5 sessions (n=7,520)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 4% against the same quarter a year earlier
profit rose 17% year on year
net margin widened from 23.1% to 23.6%
Going against it
nothing clear in the filed numbers
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
2026-06-30 · standalone
1,814
572
429
201.66
23.6%
Q4 FY26
2026-03-31 · standalone
1,710
531
395
185.85
23.1%
Q3 FY26
2025-12-31 · standalone
1,724
509
376
176.92
21.8%
Q2 FY26
2025-09-30 · standalone
1,757
546
415
195.42
23.6%
Q1 FY26
2025-06-30 · standalone
1,738
493
366
172.17
21.0%
Q4 FY25
2025-03-31 · standalone
1,605
483
367
172.72
22.9%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average-2.9%
Versus 200-day average-3.5%
Below 52-week high-19.5%
Above 52-week low+4.2%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)24.3
Higher closes in last 51 of 5
Six-month return−0.47%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)1.89%
Volume versus 20-day1.0x
Median daily turnoverRs 19.8 cr
Peers
Healthcare · 67 classified companies
ABBOTINDIA trades at 34.5× trailing earnings against an industry median of 44.0× across 64 other classified companies in its industry — cheaper than them, by 22%. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.
largest twelve by market capitalisation. Market cap and P/E need filed financials, so blanks are companies whose filings have not been read yet
Recent sessions
what this stock has matched since the engine went live
This is the live record, not the backtest — the scans this stock actually appeared in on each stored session. A name that keeps reappearing is in a persistent condition; a one-day appearance usually is not.